New strategies for allergen immunotherapy

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 2, Issue 2, 2008, Pages 92-101

  Carnés, Jerónimo ^a   Robinson, Douglas S ^a  

^a Research and Development Department   (Spain)

Author keywords

Allergen immunotherapy; Allergen CpG fusion; Allergen fusion proteins; Allergoids; Anti IgE; Depigmented allergen extracts; MPL; Peptides; Recombinant allergens; Sublingual immunotheraphy

Indexed keywords

ALLERGEN; ALLERGOID; ALUMINUM HYDROXIDE; COLECALCIFEROL; DNA VACCINE; FREUND ADJUVANT; GAMMA INTERFERON; HISTAMINE; HYBRID PROTEIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN E; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G ANTIBODY; IMMUNOGLOBULIN G4; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 10; INTERLEUKIN 5; LIPOPOLYSACCHARIDE; LIPOSOME; OMALIZUMAB; PEPTIDE DERIVATIVE; PHOSPHORYL LIPID A; PLACEBO; POLLINEX QUATTRO; RECOMBINANT ALLERGEN; RECOMBINANT BET V; SAPONIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UNINDEXED DRUG; VACCINE;

ALLERGIC DISEASE; ALLERGIC RHINITIS; ASTHMA; B LYMPHOCYTE; BINDING SITE; CELLULAR IMMUNITY; CLINICAL TRIAL; CPG ISLAND; DISEASE SEVERITY; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG SAFETY; HUMAN; IMMEDIATE TYPE HYPERSENSITIVITY; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOTHERAPY; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; REVIEW; RHINOCONJUNCTIVITIS; T LYMPHOCYTE; UNSPECIFIED SIDE EFFECT;

ALLERGENS; ANIMALS; B-LYMPHOCYTES; CLINICAL TRIALS AS TOPIC; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; IMMUNOTHERAPY; PATENTS AS TOPIC; T-LYMPHOCYTES; VACCINES;

EID: 55849083558     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221308784543610     Document Type: Review

References (83)

1. Kay AB. Allergy and allergic diseases. First of two parts. N Engl J Med 2001; 344(1): 30-37.
2. Kay AB. Allergy and allergic diseases. Second of two parts. N Engl J Med 2001; 344(2): 109-113.
3. Ling EM, Smith T, Nguyen XD, et al. Relation of CD4+CD25+ regulatory T-cell suppression of allergen-driven T-cell activation to atopic status and expression of allergic disease. Lancet 2004; 363: 608-615.
4. Bousquet J, Lockey R, Malling HJ. World Health Organization Position Paper. Allergen immunotherapy: therapeutical vaccines for allergic diseases. Allergy 1998; 53 (54): S3-S4.
5. Nelson HS. Allergen immunotherapy: Where is it now? J Allergy Clin Immunol 2007; 119: 769-777.
6. Lin MS, Tanner E, Lynn J, Friday GA Jr. Nonfatal systemic allergic reactions induced by skin testing and immunotherapy. Ann Allergy 1993; 71: 557-562.
7. Tinkelman DG, Cole WO III, Tunno J. Immunotherapy: a one year prospective study to evaluate risk factors of systemic reactions. J Allergy Clin Immunol 1995; 95: 8-14.
8. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. UK Immunotherapy Study Group Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006; 117(2): 319-325
9. Committee of the Safety of Medicines. CSM update: desensitization vaccines. Br Med J 1986; 292: 293: 948.
10. Akdis M, Akdis CA. Mechanisms of allergen immunotherapy. J Allergy Clin Immunol 2007; 119: 780-789.
11. Robinson DS, Larch M, Durham SR. Tregs and allergic disease. J Clin Invest 2004; 114(10): 1389-11397.
12. Wine Y, Cohen-Hadar N, Freeman A, Frolow F. Elucidation of the mechanism and end products of glutaraldehyde crosslinking reaction by X-ray structure analysis. Biotechnol Bioeng 2007; 98(3): 711-718.
13. Guerra F, Daza JC, Almeda E. Immunotherapy with a depigmented, polymerized vaccine of Olea europaea pollen allergens significantly reduces specific bronchial and skin test reactivity in sensitized patients after one year of treatment. J Investig Allergol Clin Immunol 2003; 13: 108-117.
14. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985; 76: 397-401.
15. Ibero M, Castillo MJ. Significant improvement of specific bronchial hyperreactivity in asthmatic children after 4 months of treatment with a modified extract of dermatophagoides pteronyssinus. J Investig Allergol Clin Immunol 2006; 16(3): 194-202.
16. Ferrer A, Garcia-Sellos J. Significant improvement in symptoms, skin test, and specific bronchial reactivity after 6 months of treatment with a depigmented, polymerized extract of Dermatophagoides pteronyssinus and D. farinae. J Investig Allergy Clin Immunol 2003; 13(4): 244-251.
17. Akdis CA, Blaser K. Mechanisms of allergen-specific immunotherapy. Allergy 2000; 55(6): 522-530.
18. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J Allergy Clin Immunol 1993; 91(3): 709-722.
19. Casanovas M, Fernandez-Caldas E, Alamar R, Basomba A. Comparative study of tolerance between unmodified and high doses of chemically modified allergen vaccines of Dermatophagoides pteronyssinus. Int Arch Allergy Immunol 2005; 137(3): 211-218.
20. Berrens, L.: WO9406821 (1994).
21. Alvarez-Cuesta E, Aragoneses-Gilsanz E, Martin-Garcia C, Berges-Gimeno P, Gonzalez-Mancebo E, Cuesta-Herranz J. Immunotherapy with depigmented glutaraldehyde-polymerized extracts: changes in quality of life. Clin Exp Allergy 2005; 35(5): 572-578. Erratum in: Clin Exp Allergy 2005; 35(11): 1504.
22. García-Robaina JC, Sánchez I, de la Torre F, Fernández-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006; 118(5): 1026-1032.
23. Colás C, Monzón S, Venturini M, Lezaun A. Double-blind, placebo-controlled study with a modified therapeutic vaccine of Salsola kali (Russian thistle) administered through use of a cluster schedule. J Allergy Clin Immunol 2006; 117(4): 810-816.
24. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985; 76: 397-401.
25. Pajno GB. Sublingual immunotherapy: the optimism and the issues. J Allergy Clin Immunol 2007; 119: 796-801.
26. Wilson DR, Torres LM, Durham SR. Sublingual immunotherapy for allergic rhinitis: a systematic review and meta-analysis. Allergy 2005; 60: 4-12.
27. Calamita Z, Saconato H. Pela AB, Atallah AN. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized-clinical trials using the Cochrane collaboration method. Allergy 2006; 61: 1162-1172.
28. Pajno GB, Caminiti L, Vita D, et al. Sublingual immunotherapy in mite-sensitized children with atopic dermatitis: a randomized, double-blind, placebo-controlled study. J Allergy Clin Immunol 2007; 120(1): 164-170.
29. Enrique E, Pineda F, Malek T, et al. Sublingual immunotherapy for hazelnut food allergy: a randomized, double-blind, placebo-controlled study with a standardized hazelnut extract. J Allergy Clin Immunol 2005; 116(5): 1073-1079.
30. Hansen KS, Khinchi MS, Skov PS, Bindslev-Jensen C, Poulsen LK, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004; 59(1): 45-53.
31. Passalacqua G, Albano M, Fregonese L, et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinoconjunctivitis. Lancet 1998; 351(9103): 629-632.
32. Kool M, Soullie T, van Nimwegen M, et al. Alum adjuvant boosts adaptive immunity by inducing uric acid and activating inflammatory dendritic cells. J Exp Med 2008;
33. Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin Exp Allergy 2004; 34(9): 1373-1378.
34. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 2001; 56(6): 498-505.
35. van Ree R, Chapman MD, Ferreira F, et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008; 63(3): 310-326.
36. O'Neil SE, Heinrich TK, Hales BJ, et al. The chitinase allergens Der p 15 and Der p 18 from Dermatophagoides pteronyssinus. Clin Exp Allergy 2006; 36(6): 831-839.
37. Valenta R, Niederberger V. Recombinant allergens for immunotherapy. J Allergy Clin Immunol 2007; 119: 826-830.
38. Jutel M, Jaeger L, Suck R, Meyer H, Fiebig H, Cromwell O. Allergen-specific immunotherapy with recombinant grass pollen allergens. J Allergy Clin Immunol 2005; 116(3): 608-613.
39. Pauli G, Malling H, Rak S, et al. Clinical efficacy of subcutaneous immunotherapy in birch pollen allergic patients: a randomized-double-blind placebo controlled study ith recomninant Bet v 1 versus natural Bet v 1 or standardized birch extract. In: Valenta R, Akdis C, Bohle B, ed., 25th Congress of the European Academy of Allergology and Clinical Immunology 2006; 28 [Abstract 83]
40. Piboonpocanun S, Malainual N, Jirapongsananuruk O, Vichyanond P, Thomas WR. Genetic polymorphisms of major house dust mite allergens. Clin Exp Allergy 2006; 36(4): 510-516.
41. Niederberger V, Horak F, Vrtala S, et al. Vaccination with genetically engineered allergens prevents progression of allergic disease. Proc Natl Acad Sci USA 2004; 101 (2): 14677-14682.
42. Larché M. Update on the current status of peptide immunotherapy. J Allergy Clin Immunol 2007; 119: 906-909.
43. Norman PS, Ohman JL Jr, Long AA, et al. Treatment of cat allergy with T-cell reactive peptides. Am J Respir Crit Care Med 1996; 154: 1623-1628.
44. Maguire P, Nicodemus C, Robinson D, Aaronson D, Umetsu DT. The safety and efficacy of Allervax CAT in cat allergic patients. Clin Immunol 1999; 93(3): 222-231.
45. Haselden BM, Kay AB, Larché M. Immunoglobulin E-independent major histocompatibility complex-restricted T cell peptide epitope-induced late asthmatic reactions. J Exp Med 1999; 189(12): 1885-1894.
46. Oldfield WL, Kay AB, Larche M. Allergen-derived T cell peptide-induced late asthmatic reactions precede the induction of antigen-specific hyporesponsiveness in atopic allergic asthmatic subjects. J Immunol 2001; 167(3): 1734-1739.
47. Oldfield WL, Kay AB, Larché M. Effect of T-cell peptides derived from Feld1 on allergic reactions and cytokine production in patients sensitive to cats: a randomised controlled trial. Lancet 2002; 360(9326): 47-53.
48. Müller U, Akdis CA, Fricker M, et al. Successful immunotherapy with T-cell epitope peptides of bee venom phospholipase A2 induces specific T-cell anergy in patients allergic to bee venom. J Allergy Clin Immunol 1998; 101: 747-754.
49. Fellrath JM, Kettner A, Dufour N, et al. Allergen-specific T-cell tolerance induction with allergen-derived long synthetic peptides: results of a phase I trial. J Allergy Clin Immunol 2003; 111(4): 854-861.
50. Tarzi M, Klunker S, Texier C, Verhoef A, et al. Induction of interleukin-10 and suppressor of cytokine signaling-3 gene expression following peptide immunotherapy. Clin Exp Allergy 2006; 36(4): 465-474.
51. Casale TB, Stokes JR. Immunomodulators for allergic respiratory disorders. J Allergy Clin Immunol 2008; 121(2): 288-296.
52. Kuehr J, Brauburger J, Zielen S, et al. Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis. J Allergy Clin Immunol 2002; 109(2): 274-280.
53. Casale TB, Busse WW, Kline JN, et al. Immune Tolerance Network Group Omalizumab pretreatment decreases acute reactions after rush immunotherapy for ragweed-induced seasonal allergic rhinitis. J Allergy Clin Immunol 2006; 117(1): 134-140.
54. Spiegelberg HL, Horner AA, Takabayashi K, Raz E. Allergen-immunostimulatory oligodeoxynucleotide conjugate: a novel allergoid for immunotherapy. Curr Opin Allergy Clin Immunol 2002; 2(6): 547-551.
55. Till SJ, Francis JN, Nouri-Aria K, Durham SR. Mechanisms of immunotherapy. J Allergy Clin Immunol 2004; 113(6): 1025-1034.
56. Tighe H, Takabayashi K, Schwartz D, et al. Conjugation of immunostimulatory DNA to the short ragweed allergen amb a 1 enhances its immunogenicity and reduces its allergenicity. J Allergy Clin Immunol 2000; 106: 124-134.
57. Creticos PS, Schroeder JT, Hamilton RG, et al. Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med 2006; 355(14): 1445-1455.
58. Busse W, Gross G, Korenblat P, et al. Phase 2/3 study of the novel vaccine Amb a 1 immunostimulatory oligodeoxyribonucleoside conjugate AIC in ragweed allergic adults [abstract]. J Allergy Clin Immunol 2006; 117: S88-S889.
59. Basomba A, Tabar AI, de Rojas DH, et al. Allergen vaccination with a liposome-encapsulated extract of Dermatophagoides pteronyssinus: a randomized, double-blind, placebo-controlled trial in asthmatic patients. J Allergy Clin Immunol 2002; 109(6): 943-948.
60. Roy K, Mao HQ, Huang SK, Leong KW. Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy. Nat Med 1999; 5(4): 387-391.
61. Bauer R, Scheiblhofer S, Kern K, et al. Generation of hypoallergenic DNA vaccines by forced ubiquitination: preventive and therapeutic effects in a mouse model of allergy. J Allergy Clin Immunol 2006; 118(1): 269-276.
62. Gabler M, Scheiblhofer S, Kern K, et al. Immunization with a low-dose replicon DNA vaccine encoding Phl p 5 effectively prevents allergic sensitization. J Allergy Clin Immunol 2006; 118(3): 734-741.
63. Zhang K, Kepley CL, Terada T, Zhu D, Perez H, Saxon A. Inhibition of allergen-specific IgE reactivity by a human Ig Fcgamma-Fcepsilon bifunctional fusion protein. J Allergy Clin Immunol 2004; 114(2): 321-327.
64. Zhu D, Kepley CL, Zhang K, Terada T, Yamada T, Saxon A. A chimeric human-cat fusion protein blocks cat-induced allergy. Nat Med 2005; 11(4): 446-449.
65. Razafindratsita A, Saint-Lu N, Mascarell L, et al. Improvement of sublingual immunotherapy efficacy with a mucoadhesive allergen formulation. J Allergy Clin Immunol 2007; 120(2): 278-285.
66. Van Oosterhout AJ, Van Esch B, Hofman G, et al. Allergen immunotherapy inhibits airway eosinophilia and hyperresponsiveness associated with decreased IL-4 production by lymphocytes in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1998; 19(4): 622-628.
67. van Oosterhout, A., Kapsenberg, M.L., Weller, F.R., Taher, Y.A., Maria, L., van Esch, E.C.A., Vissers, J.L.M.: US200757154A1 (2007).
68. Barrat FJ, Cua DJ, Boonstra A, et al. in vitro Generation of interleukin 10-producing regulatory CD4(+) T cells is induced by immunosuppressive drugs and inhibited by T helper type 1 (Th1)-and Th2-inducing cytokines. J Exp Med 2002; 195(5): 603-616.
69. Van Overtvelt L, Lombardi V, Razafindratsita A, et al. IL-10-inducing adjuvants enhance sublingual immunotherapy efficacy in a murine asthma model. Int Arch Allergy Immunol 2008; 145(2): 152-162.
70. Kumar M, Behera AK, Hu J, Lockey RF, Mohapatra SS. IFN-gamma and IL-12 plasmid DNAs as vaccine adjuvant in a murine model of grass allergy. J Allergy Clin Immunol 2001; 108(3): 402-408.
71. DeKruyff, R.H., Umetsu, D.T.: US20006086898 (2000).
72. Johansen P, Senti GJ. Martinez GJM, et al. Toll-like receptor ligands as adjuvants in allergen-specific immunotherapy. Clin Exp Allergy 2005; 35: 1591-1598.
73. Holt, P., Thomas, W., Tobagus, T.I.: US20070122417 (2007).
74. Lamping, N., Crameri, R., Fluckinger, S., Daigle, I.: US20050281816A1 (2005).
75. Koppelman, S.J.: US20070190069 (2007).
76. Fochl, M., Mahler, V., Sperr, W.R., Valent, P., Kraft, D., Valenta, R.: US2007724431 (2007).
77. O'Hehir, R., Rolland, J.: US20080075725 (2008).
78. Flicker, S., Steinberger, P., Kraft, D., Valenta, R.: US20077288381 ( 2007).
79. Moldt, P., Pedersen, G., Theobald, K., Flanagan, M.: US20060269576 ( 2006).
80. Jeon, S.-Y., Nahm, D.-H.: US20080038252 (2008).
81. Pajno GB, Barberio G, De Luca F, Morabito L, Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001; 31(9): 1392-1397.
82. Jacobsen L, Niggemann B, Dreborg S, et al. (The PAT investigator group). Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007; 62(8): 943-948.
83. Holt PG, Sly PD. Prevention of allergic respiratory disease in infants: current aspects and future perspectives. Curr Opin Allergy Clin Immunol 2007; 7(6): 547-555.